<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04642768</url>
  </required_header>
  <id_info>
    <org_study_id>KETO-SHOCK 1-10-72-209-20</org_study_id>
    <nct_id>NCT04642768</nct_id>
  </id_info>
  <brief_title>Treatment With the Ketone Body 3-hydroxybutyrate in Patients With Cardiogenic Shock</brief_title>
  <acronym>KETO-SHOCK1</acronym>
  <official_title>Treatment With the Ketone Body 3-hydroxybutyrate in Patients With Cardiogenic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background Cardiogenic shock is a life-threatening state of acute heart failure with severely&#xD;
      depressed blood pressure and organ perfusion. The 30-day mortality is reported as high as&#xD;
      50%. To date, no randomized trial has documented a survival benefit of any medical treatment&#xD;
      in this patient group. In a first-in-man study the investigators have recently discovered&#xD;
      that treatment with ketone bodies increases cardiac output by 2 liters per minute.&#xD;
&#xD;
      Objective The present study aims to examine the direct effects of ketone body supplements on&#xD;
      the heart function in patients hospitalized with cardiogenic shock. Also, the aim is to&#xD;
      determine the relative need for medical circulatory support following ketone body supplement.&#xD;
&#xD;
      Design A randomized double-blind cross-over study of the hemodynamic effect of enteral ketone&#xD;
      ester versus placebo in 12 patients with cardiogenic shock&#xD;
&#xD;
      Methods Right heart catheterization will be installed to monitor cardiac pressures and&#xD;
      output. The investigators will observe heart function with transthoracic echocardiography.&#xD;
      Blood- and urine samples will be analyzed for electrolytes, energy substrates and vasoactive&#xD;
      substances. Organ perfusion is to be examined by renal ultrasonography and near-infrared&#xD;
      spectroscopy for measuring cerebral and peripheral circulation.&#xD;
&#xD;
      Perspectives This investigation may grant essential knowledge on ketosis in cardiogenic&#xD;
      shock. This may lead to larger clinical trials, and hopefully a new and better treatment for&#xD;
      patients with cardiogenic shock.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Output (L/min) area under curve</measure>
    <time_frame>3 hours</time_frame>
    <description>Right Heart Catheterization (by thermodilution)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac output (L/min)</measure>
    <time_frame>1 hour</time_frame>
    <description>Right Heart Catheterization (by thermodilution)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Filling Pressure (mmHg) area under curve</measure>
    <time_frame>3 hours</time_frame>
    <description>Right Heart Catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Power Output (W) area under curve</measure>
    <time_frame>3 hours</time_frame>
    <description>mean arterial pressure x cardiac output/451</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mixed Venous Saturation (%) area under curve</measure>
    <time_frame>3 hours</time_frame>
    <description>Right Heart Catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction (%) area under curve</measure>
    <time_frame>3 hours</time_frame>
    <description>Echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hourly urinary output (mL/hour) area under curve</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Perfusion (mL/min)</measure>
    <time_frame>1 hours</time_frame>
    <description>Renal doppler ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Lactate (mmol/L) area under curve</measure>
    <time_frame>3 hours</time_frame>
    <description>Arterial blood gas measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative doses of inotropes and vasopressors during the 3 hour studyperiod</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Perfusion area under curve</measure>
    <time_frame>3 hours</time_frame>
    <description>Near-infrared spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral Perfusion area under curve</measure>
    <time_frame>3 hours</time_frame>
    <description>Near-infrared spectroscopy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>3-Hydroxybutyrate treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KetoneAid Ketone Ester 0,5g/kg (max. 50g) bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin-base isocaloric placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>KetoneAid Ketone Ester</intervention_name>
    <description>Commercially available ketone supplement</description>
    <arm_group_label>3-Hydroxybutyrate treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>Commercially available maltodextrin supplement</description>
    <arm_group_label>Placebo Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ongoing treatment with inotropes and/or vasopressors because of cardiogenic shock as&#xD;
             judged by the clinicians&#xD;
&#xD;
          -  Patients are required at some point in time to have had &gt; 1 of the following: systolic&#xD;
             blood pressure &lt; 90 mmHg; arterial blood lactate ≥ 2.5mmol/l; organ hypoperfusion&#xD;
             (e.g. urinary output &lt; 0.5 ml/kg/hour or SvO2 &lt;55% with normal PaO2 and Hgb)&#xD;
&#xD;
          -  LVEF &lt; 40%&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other primary causes of shock (hypovolemia, hemorrhage, severe infection or sepsis,&#xD;
             pulmonary embolism or anaphylaxis),&#xD;
&#xD;
          -  Shock due to mechanical complication to myocardial infarction (papillary muscle&#xD;
             rupture, rupture of the ventricular septum or rupture of free wall)&#xD;
&#xD;
          -  INTERMACS level 1 or 2 [18] with unstable or sliding hemodynamics on&#xD;
             inotropes/vasopressors&#xD;
&#xD;
          -  Use of or probable need for mechanic circulatory support (e.g. left ventricular&#xD;
             assistant device, IMPELLA, extracorporeal membrane oxygenation)&#xD;
&#xD;
          -  Recent post-cardiotomy cardiogenic shock (defined as thoracic surgery with the last 3&#xD;
             days)&#xD;
&#xD;
          -  Inability to position a nasogastric tube&#xD;
&#xD;
          -  Severe gastroparesis or abdominal distension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kristoffer Berg-Hansen, MD</last_name>
    <phone>+45 60540700</phone>
    <email>krisbe@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Henrik Wiggers, Prof.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <state>Midtjylland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristoffer Berg-Hansen</last_name>
      <phone>60540700</phone>
      <email>krisbe@rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Kristoffer Berg-Hansen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Ketone bodies</keyword>
  <keyword>β-hydroxybutyrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

